泰励生物，拟港股上市

Core Viewpoint - TaiLi Bio is a clinical-stage biopharmaceutical company focused on discovering and developing innovative cancer therapies, with its core candidate drug TSN1611 being a selective oral KRAS G12D inhibitor [1][3]. Group 1: Company Overview - TaiLi Bio was established in 2017 and has submitted its listing application to the Hong Kong Stock Exchange [1]. - The company has a pipeline that includes four candidate drugs, with TSN1611 currently in Phase 2 clinical trials in the US and China [3]. Group 2: Financial Performance - The company reported net losses of 70.461 million yuan and 123 million yuan for the first three quarters of 2024 and 2025, respectively [1][6]. - Research and development expenses for the same periods were 72.813 million yuan and 91.17 million yuan [6]. Group 3: Business Model and Strategy - TaiLi Bio's business model focuses on the independent discovery and development of innovative drugs in the oncology field, particularly small molecule drugs and ADC candidates [3]. - The company aims to accelerate the clinical development and commercialization of TSN1611 and plans to pursue external collaborations to maximize the global value of its technology platform and product pipeline [3][4]. Group 4: Research and Development - The company has established three core self-developed technology platforms that provide a competitive advantage in the development of small molecules and ADCs [3]. - As of January 23, 2026, TaiLi Bio holds 97 patents and patent applications [6]. Group 5: Regulatory Status - As of the latest update, TaiLi Bio has not received any regulatory approvals for its candidate drugs and has not generated any revenue from product sales [6].